[Effect of Puerarin on platelet activating factors CD63 and CD62P, plasminogen activator inhibitor and C-reactive protein in patients with unstable angia pectoris].
OBJECTIVE
To explore the action of platelet surface activity protein (platelet granule membrane protein CD63 and lysosome membrane protein CD62P), plasminogen activator inhibitor (PAI-1) and C-reactive protein (C-RP) in occurrence and development of unstable angina pectoris (UAP), and the effect of Puerarin on them.


METHODS
Patients with UAP were randomly divided into the treated group (32 cases, treated with Puerarin) and the control group (27 cases, treated with Ticlid), the therapeutic course was 4 weeks for both groups. Changes of CD63, CD62P, PAI-1 and C-RP before and after treatment were observed.


RESULTS
The levels of CD63, CD62P, PAI-1 and C-RP were higher in UAP patients than those in normal subjects and in the patients with stable angina pectoris (P < 0.05 or P < 0.01). These parameters were increased along with the aggravating of patients in Braunwald's degree. After 4-week treatment, the above-mentioned parameters lowered in both groups (P < 0.05 or P < 0.01), and comparison between the two groups showed no significant difference statistically.


CONCLUSIONS
Platelet activation, plasminogen activator and C-RP play important roles in the occurrence and development of UAP. The obvious effect of Puerarin in anti-platelet activation, improving plasminogen activator and relieving inflammatory reaction was of great importance in preventing the occurrence and development of acute coronary syndrome clinically.
Luo
Z R
ZR
Department of Cardiology, Fuzhou General Hospital of PLA, Fuzhou 350025.
Zheng
B
B
D000328:Adult; D000789:Angina, Unstable / Q000097:blood / Q000188:drug therapy*; D015703:Antigens, CD / Q000378:metabolism*; D002097:C-Reactive Protein / Q000378:metabolism; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019007:P-Selectin / Q000097:blood*; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D015539:Platelet Activation; D010980:Platelet Membrane Glycoproteins / Q000378:metabolism*; D016037:Single-Blind Method; D060149:Tetraspanin 30; D014665:Vasodilator Agents / Q000627:therapeutic use*
D015703:Antigens, CD; C554586:CD63 protein, human; D007529:Isoflavones; D019007:P-Selectin; D017395:Plasminogen Activator Inhibitor 1; D010980:Platelet Membrane Glycoproteins; D060149:Tetraspanin 30; D014665:Vasodilator Agents; D002097:C-Reactive Protein; C033607:puerarin